GREY:DGCRF - Post by User
Post by
Dibah42on Jan 11, 2013 11:17am
217 Views
Post# 20825713
Problem solved? Or in denial?
Problem solved? Or in denial? DiagnoCure (TSX: CUR) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Corporation has also granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate...
The conspicuous absence of any reference to problems with Signal in the above press release could mean that there has been a resolution; or, that management is still loathe to talk about the issue. My gut says it is the latter. But I could be wrong.
And the recent spike could be a lot of us padding our TFSA's.
Cheers, from the Jmaa el Fnaa. About to hit the High Atlas followed by some desert camping.